Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 June 2019 | Story Zama Feni | Photo Zama Feni
CrazySocksForDocs
UFS medical students displaying multi-coloured mismatched socks as they heeded the call of the #CrazySocks4Doc campaign to raise awareness about mental health in the medical profession.

Hundreds of pairs of socks were dished out to medical students last week during the campus launch of the #CrazySocks4Docs (#CS4D) awareness campaign that seeks to help break the silence around mental-health illness in the medical profession.
 
More than 600 medical students from the University of the Free State (UFS) School of Internal Medicine heeded the call by the non-governmental organisation, Ithemba Foundation, whose mission is to educate the public around mental health – specifically depression and related diseases such as anxiety disorders – and to support research.

On Monday, 3 June 2019, the Ithemba Foundation launched the CS4D campaign countrywide at all tertiary institutions with medical schools to help break the silence around mental health in the medical profession. 

“We have ensured a sponsorship of 10 000 pairs of mismatched socks for medical students, to be distributed according to student numbers at each medical campus,” Ithemba Foundation said in a statement.

Students waking up to the call

A large number of UFS medical students gladly embraced the call and helped themselves to pairs of multi-coloured socks at the James Moroka Building foyer on the Bloemfontein Campus.

Judy Modise, a second-year medical student, said she was impressed with the initiative.
“I think this is a very interesting campaign, as we all know the devastating effects of mental health in society, and more specifically on doctors,” she said.

UFS has risen to the challenge

In a widely published opinion piece on mental health in October last year, UFS Rector and Vice-Chancellor Prof Francis Petersen, stated that one in every three South Africans suffers from some form of mental disorder.

He mentioned that, “The university has just released a first draft of its first-ever Student Mental Health Policy.”

“This policy seeks to redress the inequalities and disadvantages created by prejudice and discrimination against persons with mental-health disabilities and difficulties,” said Prof Petersen.
 
Destigmatising mental health is key

The Ithemba Foundation further stated that, “It is critical that we start the conversation around mental health in the health profession – especially among the next generation of medical professionals, as the stigma surrounding the illness in doctors persists. Wearing mismatched, brightly-coloured socks may seem like a weird place to begin, but to care for others, we also have to care for ourselves and each other.”

The purpose of the campaign is to create awareness about the highly stressful nature of the medical profession; the need for doctors to seek help when needed, both mental and physical; the need for those in the health profession to help one another and the need to reshape the culture of the health care industry and to ensure that you will have a new mindset concerning your own mental health. 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept